Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study.

Lotery A, Clemens A, Tuli R, Xu X, Shimura M, Nardi M, Ziemssen F, Dunger-Baldauf C, Tadayoni R, LUMINOUS™ study group

Open source

DOI
10.1038/s41433-021-01702-y
Published
2022 Aug
Container
Eye (London, England)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41433-021-01702-y,
  title = {Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study.},
  author = {Lotery A and Clemens A and Tuli R and Xu X and Shimura M and Nardi M and Ziemssen F and Dunger-Baldauf C and Tadayoni R and LUMINOUS™ study group},
  year = {2022},
  journal = {Eye (London, England)},
  doi = {10.1038/s41433-021-01702-y},
  url = {https://doi.org/10.1038/s41433-021-01702-y}
}

RIS

TY  - JOUR
TI  - Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study.
AU  - Lotery A
AU  - Clemens A
AU  - Tuli R
AU  - Xu X
AU  - Shimura M
AU  - Nardi M
AU  - Ziemssen F
AU  - Dunger-Baldauf C
AU  - Tadayoni R
AU  - LUMINOUS™ study group
PY  - 2022
JO  - Eye (London, England)
DO  - 10.1038/s41433-021-01702-y
UR  - https://doi.org/10.1038/s41433-021-01702-y
ER  - 

APA

A, L., A, C., R, T., X, X., M, S., M, N., F, Z., C, D., R, T., & group, L. S. (2022). Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study.. Eye (London, England). https://doi.org/10.1038/s41433-021-01702-y

Source records